Cisplatin as single-agent chemotherapy in patients with liver dysfunction due to metastases.
BACKGROUND
Chemotherapeutic options are often limited for patients with hepatic dysfunction induced by advanced metastases. The toxicity and efficacy of cytotoxic drugs are often unpredictable due to altered drug activation or inactivation and excretion. Therefore, numerous chemotherapeutic agents should not be administered to patients with liver failure.


METHODS
We retrospectively analysed 14 patients with solid tumours presenting with liver dysfunction induced by metastasis who were treated with cisplatin single-agent chemotherapy.


RESULTS
Tolerance of therapy was acceptable with 1 grade I and 1 grade II renal toxicity. 6 patients experienced grade III haematological toxicity. Partial remission of the disease was observed in 6 cases, and 6 patients could receive combination chemotherapy after improvement of liver function. The median overall survival of the patient cohort was 4.8 months.


CONCLUSIONS
Cisplatin monotherapy may thus be considered as a treatment option for patients with liver dysfunction induced by different solid tumours.
Wilop
Stefan
S
Medizinische Klinik IV, Universitätsklinikum Aachen, RWTH Aachen, Germany.
Dada
Reyad
R
Galm
Oliver
O
Jousten
Peter
P
Osieka
Rainhardt
R
Jost
Edgar
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D017093:Liver Failure / Q000209:etiology* / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D002945:Cisplatin